Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06898788 · ClinicalTrials.gov registry record · Early Phase 1
Probiotic Administration for Adolescent Depression
A Early Phase 1 study of Depression, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT06898788: Recruiting Early Phase 1 study of Depression, sponsored by University of California, San Francisco.
NCT06898788 is a Early Phase 1 study of Depression that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 77 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06898788, a Early Phase 1 study of Depression, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.
Primary Outcome
Measured with fMRI.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Visbiome
Study Locations (1)
California
- UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT06898788 shows while recruiting
NCT06898788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06898788 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06898788 about?
NCT06898788 is a clinical study titled "Probiotic Administration for Adolescent Depression". This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.
What is the current status of trial NCT06898788?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 77 participants. The study started on 2025-05-15. Estimated completion is 2026-12.
What conditions does trial NCT06898788 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06898788?
The interventions under investigation include: Placebo (DRUG), Visbiome (DRUG).
Who is sponsoring clinical trial NCT06898788?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06898788 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06898788's enrollment target sits among peer trials
77 383rd of 679 higher than 297 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
RECRUITING · Early Phase 1
-
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
ACTIVE NOT RECRUITING · Early Phase 1
-
Testing a Transdiagnostic TMS Treatment Target
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy